Abbvie earnings were $6.3B for the trailing 12 months ending Jun 30, 2026, with 68.2% growth year over year. The latest ABBV earnings report on Jun 30, 2026 announced Q2 2026 earnings of $3.6B, up 419.9% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, ABBV reported annual earnings of $4.2B, with -1.2% growth.
ABBV past earnings growth
How has ABBV's earnings growth performed historically?
On ABBV's earnings call on Jul 31, 2026, Abbvie (NYSE: ABBV) reported Q2 2026 earnings per share (EPS) of $2.04, up 292.31% year over year. Total ABBV earnings for the quarter were $3.61 billion. In the same quarter last year, Abbvie's earnings per share (EPS) was $0.52.
As of the last Abbvie earnings report, Abbvie is currently profitable. Abbvie's net profit (also called net income) for the twelve months ending Jun 30, 2026 was $6.31 billion, a 67.69% increase year over year.
What was ABBV's earnings growth in the past year?
As of Abbvie's earnings date in Jul 31, 2026, Abbvie's earnings has grown 68.25% year over year. This is 24.34 percentage points higher than the US Drug Manufacturers - General industry earnings growth rate of 43.9%. ABBV earnings in the past year totalled $6.31 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.